紫杉醇联合卡铂方案化疗同步放疗治疗Ⅲ期子宫颈癌的临床效果  

Clinical effect of paclitaxel and carboplatin regimen chemotherapy combined with radiotherapy in treatment of stage Ⅲ cervical cancer

作　　者：刘楷东 陈明晓[1] 任俊丽[1] 王萍[2] 张继东[1] Liu Kaidong;Chen Mingxiao;Ren Junli;Wang Ping;Zhang Jidong(Department of Abdomen Ward 2, Radiotherapy Center, Shanxi Provincial Cancer Hospital, Taiyuan 030013, China;Department of Gynecology 2, Shanxi Provincial Cancer Hospital, Taiyuan 030013, China)

机构地区：[1]山西省肿瘤医院放腹盆二病区,太原030013 [2]山西省肿瘤医院妇科二病区,太原030013

出　　处：《肿瘤研究与临床》2018年第12期860-863,870,共5页Cancer Research and Clinic

摘　　要：目的对比分析紫杉醇联合卡铂方案化疗同步放疗和单纯放疗治疗Ⅲ期子宫颈癌患者的疗效和不良反应。方法回顾性分析2009年5月至2012年10月山西省肿瘤医院收治的Ⅲ期子宫颈癌患者共158例,依据治疗方式不同,分为同步放化疗组86例和单纯放疗组72例,对比分析两组患者的疗效和不良反应。结果同步放化疗组和单纯放疗组患者的有效率(完全缓解+部分缓解)分别为95.3%(82/86)和84.7%(61/72),差异有统计学意义(χ2=5.15,P=0.023)。同步放化疗组与单纯放疗组1、2、3、5年生存率分别为93.0%(80/86)、77.9%(67/86)、68.6%(59/86)、60.5%(52/86)和81.9%(59/72)、61.1%(44/72)、41.7%(30/72)、36.1%(26/72),差异均有统计学意义(χ2值分别为4.55、5.29、11.56、9.30,均P<0.05);同步放化疗组和单纯放疗组近期不良反应均以骨髓抑制和胃肠道反应为主,骨髓抑制发生率分别为87.2%(75/86)和50.0%(36/72),差异有统计学意义(χ2=25.96,P<0.01);胃肠道反应发生率分别为91.9%(79/86)和20.8%(15/72),差异有统计学意义(χ2=82.04,P<0.01)。同步放化疗组和单纯放疗组放射性直肠炎发生率分别为17.4%(15/86)和16.7%(12/72),差异无统计学意义(χ2=0.017,P=0.89);放射性膀胱炎发生率分别为7.0%(6/86)和5.6%(4/72),差异无统计学意义(χ2=0.134、P=0.71)。结论紫杉醇联合卡铂方案化疗同步放疗能提高Ⅲ期子宫颈癌患者的生存率,不良反应可以耐受。Objective To compare the efficacy and toxicity of paclitaxel and carboplatin regimen concurrent chemoradiotherapy and radiotherapy alone in the treatment of stage Ⅲ cervical cancer. Methods A retrospective analysis of 158 patients with stage Ⅲ cervical cancer who were admitted to Shanxi Provincial Cancer Hospital from May 2009 to October 2012 was conducted. According to different treatment methods, 86 patients were in the concurrent chemoradiotherapy group and 72 patients were in the radiotherapy group. The efficacy and adverse reactions of the two groups were compared. Results The effective rate (complete remission + partial remission) in the concurrent radiotherapy group and radiotherapy group was 95.3% (82/86) and 84.7% (61/72), respectively, and the difference was statistically significant (χ 2 = 5.15, P = 0.023). The 1-, 2-, 3-, and 5-year survival rates of the concurrent radiotherapy group and radiotherapy group were 93.0% (80/86), 77.9% (67/86), 68.6% (59/86), 60.5% (52/86), and 81.9% (59/72), 61.1% (44/72), 41.7% (30/72), 36.1% (26/72), respectively, and the differences were statistically significant (χ 2 values were 4.55, 5.29, 11.56, 9.30, all P < 0.05). The short-term adverse reactions in the concurrent chemoradiotherapy group and radiotherapy group were mainly myelosuppression and gastrointestinal reactions, and the incidence of myelosuppression was 87.2% (75/86) and 50.0% (36/72), respectively, and the difference was statistically significant (χ 2 = 25.96, P < 0.01);the incidence of gastrointestinal reactions was 91.9% (79/86) and 20.8% (15/72), respectively, and the difference was statistically significant (χ 2 = 82.04, P < 0.01). The incidence of radiation proctitis in the concurrent radiotherapy and chemotherapy group was 17.4% (15/86) and 16.7% (12/72), respectively, and the difference was not statistically significant (χ 2 = 0.017, P = 0.89);the incidence of radiation cystitis was 7.0% (6/86) and 5.6% (4/72), respectively, and the difference was not statistically significant (χ 2 = 0.1

关 键 词：宫颈肿瘤 同步放化疗 紫杉醇 卡铂 

分 类 号：R737.33[医药卫生—肿瘤]